Background & Objectives Worldwide, osteoarthritis (OA) is a highly prevalent, chronic joint disease that causes pain, disability and loss of function. Global trends demonstrated an increase of more than 100% in years lived with disability due to OA from 1990 to 2019. However, no nonsurgical intervention exists to prevent, halt or even delay OA progression….
We Must Include Diverse Belief Models in Rheumatology Research
Information overload generated by the media, family, friends and colleagues is apparent today. Personal beliefs play an important role in how we filter and process the abundant information available and subsequently identify its utility in daily life. Regardless of professional specialty, individual beliefs underpin personal approaches to clinical care, research development and engagement with patients…
Hand Osteoarthritis: Prevalence, Incidence and Progression
Eaton et al. set out to describe the prevalence, incidence and progression of radiographic and symptomatic hand osteoarthritis (OA), and to evaluate differences according to age, sex, race and other risk factors.
Outcomes in Patients with Rheumatic Diseases & COVID-19
Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to…
Is Hydroxychloroquine Safe During Pregnancy?
Chambers et al. found no evidence of an increased risk of major structural birth defects nor any increase in a wide range of other pregnancy outcomes attributable to prenatal exposure to hydroxychloroquine.
Pregnancy Outcomes in Patients with Psoriatic Arthritis
In March A&R, Remaeus et al. reported on the results of their study, which evaluated pregnancy outcomes in relation to anti-rheumatic treatment before and during pregnancy, as a proxy of disease severity in pregnant women with psoriatic arthritis (PsA), compared with those without PsA.
Highlights from ACR Convergence’s Late-Breaking Abstracts
COVID-19 vaccination, treatments for rheumatic disease and more—the Late-Breaking Abstracts session of ACR Convergence 2021 highlighted six studies with implications for rheumatology.
Risk of IBD in Patients with Psoriasis, PsA & Ankylosing Spondylitis Starting IL-17 Inhibitors
In February A&R, Penso et al. reported on the results of their study, which explored whether patients with psoriasis, PsA and AS have a higher risk of developing IBD when treated with an IL-17 inhibitor compared with apremilast, a phosphodiesterase 4 (PDE4) inhibitor, or etanercept, a TNF inhibitor.
COVID-19 Vaccination in Patients with Rheumatic Disease
In January A&R, Simon et al. report a study to assess humoral and cellular immune responses after infection with, or vaccination against, SARS-CoV-2 in patients with B cell depletion and controls who are B cell competent, finding that B cell depletion completely blocks humoral but not T cell SARS-CoV-2 vaccination response. In the same issue, Connolly et al. evaluated disease flare and post-vaccination reactions in patients with rheumatic and musculoskeletal diseases following messenger RNA (mRNA) vaccination.
HCQ/CQ May Increase the Risk of Cardiovascular Events
A special article in the December issue of Arthritis & Rheumatology summarizes the current understanding of the cardiac toxicity of HCQ and CQ.
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 77
- Next Page »